Drugs / SHR-A1912
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05113069 | Dec 2021 → Mar 2024 | B-cell neoplasm | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06104553 | Nov 2023 → Dec 2025 | B-cell non-Hodgkin lymphoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06929624 | Apr 2025 → Mar 2027 expected | diffuse large B-cell lymphoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-A1912 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06929624 ↗ |